Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
|
30537101 |
2019 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, aberrant, ligand-free activation of the FGFR signaling pathway resulting from mutations in FGFR2 was also reported in endometrial cancer.
|
30963412 |
2019 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings uncover collective cell polarity and invasion as common targets of disease-associated FGFR2 mutations that lead to poor outcome in endometrial cancer patients.
|
30002137 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We tested the cytotoxicity of AL3818 on a panel of 7 human endometrial cancer cell lines expressing either wild-type or mutant FGFR2 and also assessed the in vivo antitumor efficacy in a murine, orthotopic AN3CA endometrial cancer model.
|
28953502 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphism, gene amplification or missense mutations of FGFR2 are associated with endometrial cancer.
|
30094104 |
2018 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p<0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177-3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096-3.696).
|
28314589 |
2017 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination of FGFR and AKT inhibition in an FGFR2-mutated endometrial cancer xenograft model enhanced modulation of transcript biomarkers from the PI3K/AKT pathway and tumor growth inhibition.
|
27550940 |
2016 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, AP24534 inhibited migration and invasion of endometrial cancer cells with FGFR2 mutations.
|
26574622 |
2016 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significance of the FGFR2-EGR1 axis in endometrial cancer progression has not been reported.
|
26294741 |
2015 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
DNAs were extracted from 72 cases of fresh-frozen endometrial cancer tissues for FGFR2 mutational analysis by HRM analysis.
|
25517871 |
2015 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of 248 patients with FGFR2 prescreening results, 27 (11%) had FGFR2(mut) endometrial cancer.
|
25981814 |
2015 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In vivo, dovitinib and NVP-BGJ398 significantly inhibited the growth of FGFR2-mutated endometrial cancer xenograft models.
|
23443805 |
2013 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine the therapeutic potential of a rational drug combination based on the simultaneous targeting of mutant-FGFR2 and mTOR-driven signaling pathways in endometrial cancer cells.
|
23468082 |
2013 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer.
|
22383975 |
2012 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Together these data suggest a potential therapeutic benefit to combining an FGFR inhibitor with standard chemotherapeutic agents in endometrial cancer therapy particularly in patients with FGFR2 mutation positive tumors.
|
23060048 |
2012 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer.
|
20106510 |
2010 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In vitro studies have shown that endometrial cancer cell lines with activating FGFR2 mutations are selectively sensitive to a pan-FGFR inhibitor, PD173074.
|
19243295 |
2009 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken into account with our recent discovery of activating FGFR2 mutations in endometrial cancer, we suggest that FGFR2 may join the list of genes that play context-dependent opposing roles in cancer.
|
19147536 |
2009 |
Malignant neoplasm of endometrium
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also observed a nonsignificant inverse association with rs889312 (MAP3K1) variant carriers [OR = 0.85 (95% CI: 0.68-1.05)] and rs1219648 (FGFR2) variant carriers [OR= 0.86 (95% CI: 0.69-1.06) and endometrial cancer risk.
|
18785201 |
2008 |
Malignant neoplasm of endometrium
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that shRNA knockdown of FGFR2 or treatment with a pan-FGFR inhibitor, PD173074, resulted in cell cycle arrest and induction of cell death in endometrial cancer cells with activating mutations in FGFR2.
|
18757403 |
2008 |
Malignant neoplasm of endometrium
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|